| Literature DB >> 25277367 |
Mette L Schousboe, Samir Ranjitkar, Rupika S Rajakaruna, Priyanie H Amerasinghe, Flemming Konradsen, Francisco Morales, Rosalynn Ord, Richard Pearce, Toby Leslie, Mark Rowland, Nahla Gadalla, Ib C Bygbjerg, Michael Alifrangis, Cally Roper1.
Abstract
BACKGROUND: Even though Plasmodium vivax has the widest worldwide distribution of the human malaria species and imposes a serious impact on global public health, the investigation of genetic diversity in this species has been limited in comparison to Plasmodium falciparum. Markers of genetic diversity are vital to the evaluation of drug and vaccine efficacy, tracking of P. vivax outbreaks, and assessing geographical differentiation between parasite populations.Entities:
Mesh:
Year: 2014 PMID: 25277367 PMCID: PMC4200131 DOI: 10.1186/1475-2875-13-392
Source DB: PubMed Journal: Malar J ISSN: 1475-2875 Impact factor: 2.979
Heterozygosity (He) at the two microsatellite loci m1501 and m3502 in every survey
| Study site | n | Year | n (%) | m1501 | MOI | n (%) | m3502 | MOI | m1501 + m3502 | Ref | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| He | He |
| |||||||||
|
|
| 386 | 2002-2006 | 352 (91.2) | 0.85 | 1.276 | 357 (92.5) | 0.74 | 1.073 | 338 (87.6) | *and [ |
|
| 55 | 2006, 2009-2010 | 53 (96.4) | 0.94 | 1.189 | 49 (89.1) | 0.80 | 1.347 | 47 (85.5) | *and [ | |
|
| 329 | 2001, 2003-2007 | 315 (95.7) | 0.91 | 1.365 | 314 (95.4) | 0.80 | 1.650 | 309309 (93.9) | *and [ | |
|
| 58 | 1996-2000, 2007 | 58 (100) | 0.42 | --- | 58 (100) | 0.73 | --- | 58 (100) | [ | |
|
| 90 | 2003-2004 | 78 (86.7) | 0.90 | --- | 79 (87.8) | 0.86 | --- | --- | [ | |
|
| 81 | 2001-2003 | 81 (100) | 0.83 | --- | 74 (91.4) | 0.90 | --- | 74 (91.4) | [ | |
|
| 92 | 1992-1998 | 91 (98.9) | 0.89 | --- | 91 (98.9) | 0.85 | --- | --- | [ | |
|
| 108 | 2004-2005 | 107 (99.1) | 0.91 | 1.907 | 108 (100) | 0.86 | 1.648 | 107 (99.1) | [ | |
|
|
| 82 | 2001-2003 | 80 (97.6) | 0.70 | --- | 82 (100) | 0.76 | --- | 80 (97.6) | [ |
|
| 130 | 1996-1997 | 113 (86.9) | 0.73 | 1.416 | 98 (75.4) | 0.57 | 1.235 | 97 (74.6) | * | |
|
| 17 | 2009 | 17 (100) | 0.22 | 1.176 | 17 (100.0) | 0.76 | 1.176 | 17 (100.0) | * | |
|
|
| 8 | 2006 | 7 (87.5) | 0.71 | 1.571 | 4 (50.0) | 1.00 | 1.235 | 3 (37.5) | * |
|
| 4 | 2000 | 4 (100.0) | 0.83 | 1.250 | 4 (100.0) | 0.83 | 2.250 | 4 (100.0) | * | |
|
| 1440 | 1992-2010 | 1356 (94.2) | 1.614 | 1335 (92.7) | 1.490 | 1134/1258 (90.1) |
PNG: Papua New Guinea. Pak/Afg: Pakistan/Afghanistan. South A: South America. The number (and percentage) of samples successfully amplified for each MS locus and for the two loci combined are shown in every survey. Multiplicty of infection (MOI) is calculated by averaging the number of alleles detected in the total number of PCR positive samples. Data not available are indicated by “---”. Reference marked as * is this study.
Figure 1Allelic diversity at the MS m1501 (A) and m3502 (B) in samples from South America (Columbia, Venezuela and Ecuador) and Asia (India, Laos, Thailand, Korea, Nepal, Pakistan and Sri Lanka). The MS alleles are divided into groups of increasing fragment size according to the number of repeats. In brackets are mentioned the number of samples included from each continent.
Genetic differentiation between populations measured by pairwise
| m1501 | Africa | South America | Asia |
|---|---|---|---|
| Africa (11) | ** | NS | |
| South America (210) | 0.1824 | ** | |
| Asia (1028) | 0.0446 | 0.0869 | |
|
|
|
|
|
| Africa (8) | ** | NS | |
| South America (197) | 0.1050 | ** | |
| Asia (1022) | 0.0049 | 0.0752 |
The pairwise significance after standard Bonferroni corrections are listed as: “**” significance at the 1% nominal level while “NS” stands for non-significant.